Surrogate endpoint biomarkers in research

Bookmark and Share
Published: 4 Aug 2016
Views: 1699
Dr Bernardo Bonanni – European Institute of Oncology, Milan, Italy

Dr Bonanni speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about "window of opportunity" trials which gauge pre-surgical patient responses to treatments against breast cancer.

He describes the range of medicines and dietary compounds which have shown chemopreventive activity, and how surrogate biomarkers can be brought to broader clincal application.